precisionmedicineonline5d
Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Denali Starts Dosing in Phase II Parkinson's Disease Study
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
manilatimes6d
Results of VVC Annual Shareholders' Meeting
TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources, ("VVC”), (TSX-V:VVC and ...
Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...